Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549833 · ClinicalTrials.gov registry record · Phase 1
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
A Phase 1 study of Glioma and Malignant Glioma, sponsored by Jennie Taylor.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02549833 is a Phase 1 study of Glioma and Malignant Glioma that has completed, run by Jennie Taylor. The registered enrollment target is 28 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02549833, a Phase 1 study of Glioma and Malignant Glioma, has completed, sponsored by Jennie Taylor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot neoadjuvant vaccine study in adults with WHO grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety and feasibility of the neoadjuvant approach; and 2) whether the regimen increases the level of type-1 chemokine CXCL10 and vaccine-specific (i.e., reactive to GBM6-AD) CD8+ T-cells in tumor-infiltrating leukocytes (TILs) in the surgically resected glioma.
Conditions Studied
Interventions
- BIOLOGICAL GBM6-AD and poly-ICLC before and after surgery
- BIOLOGICAL GBM6-AD and poly-ICLC after surgery only
Study Locations (1)
California
- University of California - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549833
The ClinicalTrials.gov registry entry for NCT02549833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The listed sponsor is Jennie Taylor, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which GBM6-AD and poly-ICLC before and after surgery is the first listed.
NCT02549833 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02549833 about?
NCT02549833 is a clinical study titled "Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma". This is a pilot neoadjuvant vaccine study in adults with WHO grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety and feasibility of the neoadjuvant approach; and 2) whether the regimen increases the level of type-1...
What is the current status of trial NCT02549833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-10-17. Estimated completion is 2024-08-31.
What conditions does trial NCT02549833 study?
This clinical trial studies the following conditions: Glioma, Malignant Glioma, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed.
What interventions are being tested in trial NCT02549833?
The interventions under investigation include: GBM6-AD and poly-ICLC before and after surgery (BIOLOGICAL), GBM6-AD and poly-ICLC after surgery only (BIOLOGICAL).
Who is sponsoring clinical trial NCT02549833?
This trial is sponsored by Jennie Taylor, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549833 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.